Payment overview · 2025
General Payments
$234.02
12 reported records · 11 companies
Healthcare provider profile · identity verified
David J Freestone, MD
Allopathic & Osteopathic Physicians|Family Medicine · ITHACA, MI · NPI 1801861851
Verified facts
What the public records show
CMS Open Payments records show David J Freestone, MD received $234.02 in general payments during 2025 across 12 reported records.
Novo Nordisk Inc accounted for 14.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 16 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Mounjaro, Ozempic.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Symbicort by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 28 records involving 28 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Xarelto by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 101 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 169 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $34.27 | 14.6% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $29.07 | 12.4% | 1 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $23.04 | 9.8% | 1 | 2025 |
| Organon LLC | Unresolved — no canonical attribution shown | $21.75 | 9.3% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $19.61 | 8.4% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $19.16 | 8.2% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $18.70 | 8.0% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $18.16 | 7.8% | 1 | 2025 |
| Neurelis, Inc. |
Neurelis, Inc. exact · evidence 2025-02-20 |
$16.82 | 7.2% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $16.78 | 7.2% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $16.66 | 7.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $234.02 | 12 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $29.07 | 1 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $23.04 | 1 | 2025 |
Source payment records
|
|||||
| NEXPLANON Normalized: nexplanon |
Drug | Organon LLC | $21.75 | 1 | 2025 |
Source payment records
|
|||||
| NUVARING Normalized: nuvaring |
Drug | Organon LLC | $21.75 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $19.61 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $19.16 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $18.70 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $18.16 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $18.16 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $18.16 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $17.58 | 1 | 2025 |
Source payment records
|
|||||
| VALTOCO Normalized: valtoco |
Drug | Neurelis, Inc. | $16.82 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $16.78 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $16.78 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $16.69 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $16.66 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 34 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 101 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 28 recipient NPIs · example record 1174296970 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
34 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
101 | 27 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
169 | 50 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 875 | 259 |
| Levothyroxine Sodium | Levothyroxine Sodium | 690 | 185 |
| Amlodipine Besylate | Amlodipine Besylate | 554 | 171 |
| Lisinopril | Lisinopril | 467 | 139 |
| Omeprazole | Omeprazole | 416 | 130 |
| Metoprolol Succinate | Metoprolol Succinate | 369 | 111 |
| Metformin Hcl | Metformin Hcl | 306 | 91 |
| Fenofibrate | Fenofibrate | 300 | 78 |
| Ezetimibe | Ezetimibe | 285 | 82 |
| Losartan Potassium | Losartan Potassium | 262 | 77 |
| Furosemide | Furosemide | 230 | 97 |
| Glipizide Er | Glipizide | 230 | 69 |
| Baclofen | Baclofen | 214 | 98 |
| Meloxicam | Meloxicam | 214 | 94 |
| Pioglitazone Hcl | Pioglitazone Hcl | 200 | 62 |
| Pravastatin Sodium | Pravastatin Sodium | 189 | 52 |
| Tamsulosin Hcl | Tamsulosin Hcl | 178 | 56 |
| Eliquis | Apixaban | 169 | 50 |
| Hydrochlorothiazide | Hydrochlorothiazide | 161 | 48 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 146 | 89 |
| Gabapentin | Gabapentin | 137 | 43 |
| Paroxetine Hcl | Paroxetine Hcl | 131 | 42 |
| Atenolol | Atenolol | 124 | 39 |
| Pantoprazole Sodium | Pantoprazole Sodium | 121 | 41 |
| Potassium Chloride | Potassium Chloride | 117 | 35 |
| Simvastatin | Simvastatin | 117 | 33 |
| Carvedilol | Carvedilol | 111 | 39 |
| Ibuprofen | Ibuprofen | 107 | 61 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 103 | 85 |
| Clopidogrel | Clopidogrel Bisulfate | 101 | 31 |
| Metformin Hcl Er | Metformin Hcl | 101 | 30 |
| Ozempic | Semaglutide | 101 | 27 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 101 | 35 |
| Warfarin Sodium | Warfarin Sodium | 101 | 22 |
| Fluticasone Propionate | Fluticasone Propionate | 100 | 51 |
| Metoprolol Tartrate | Metoprolol Tartrate | 100 | 29 |
| Sertraline Hcl | Sertraline Hcl | 91 | 29 |
| Citalopram Hbr | Citalopram Hydrobromide | 90 | 24 |
| Alendronate Sodium | Alendronate Sodium | 88 | 25 |
| Diclofenac Sodium | Diclofenac Sodium | 80 | 34 |
| Prednisone | Prednisone | 80 | 41 |
| Trazodone Hcl | Trazodone Hcl | 80 | 28 |
| Montelukast Sodium | Montelukast Sodium | 79 | 27 |
| Naproxen | Naproxen | 75 | 37 |
| Januvia | Sitagliptin Phosphate | 71 | 18 |
| Donepezil Hcl | Donepezil Hcl | 69 | 25 |
| Escitalopram Oxalate | Escitalopram Oxalate | 69 | 18 |
| Amoxicillin | Amoxicillin | 68 | 52 |
| Cephalexin | Cephalexin | 64 | 49 |
| Duloxetine Hcl | Duloxetine Hcl | 61 | 17 |
| Fluoxetine Hcl | Fluoxetine Hcl | 61 | 22 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 61 | 19 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 60 | 44 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 58 | 20 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 58 | 28 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 58 | 17 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 55 | 19 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 55 | 17 |
| Famotidine | Famotidine | 52 | 14 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 49 | suppressed |
| Finasteride | Finasteride | 48 | 14 |
| Methylprednisolone | Methylprednisolone | 48 | 43 |
| Zolpidem Tartrate | Zolpidem Tartrate | 48 | 18 |
| Allopurinol | Allopurinol | 46 | 15 |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 45 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 44 | 24 |
| Aripiprazole | Aripiprazole | 43 | 15 |
| Glipizide | Glipizide | 43 | 14 |
| Pregabalin | Pregabalin | 42 | 16 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 39 | 30 |
| Hydralazine Hcl | Hydralazine Hcl | 39 | 14 |
| Fenofibrate | Fenofibrate Nanocrystallized | 35 | 11 |
| Mounjaro | Tirzepatide | 34 | 11 |
| Buspirone Hcl | Buspirone Hcl | 33 | suppressed |
| Trulicity | Dulaglutide | 33 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 32 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 32 | 23 |
| Tramadol Hcl | Tramadol Hcl | 32 | 22 |
| Clonidine Hcl | Clonidine Hcl | 30 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 30 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 29 | suppressed |
| Fluconazole | Fluconazole | 29 | 19 |
| Levetiracetam | Levetiracetam | 29 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 28 | 11 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 28 | suppressed |
| Spironolactone | Spironolactone | 28 | 12 |
| Jardiance | Empagliflozin | 27 | suppressed |
| Azithromycin | Azithromycin | 26 | 23 |
| Bupropion Xl | Bupropion Hcl | 26 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 26 | 14 |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 26 | suppressed |
| Nitroglycerin | Nitroglycerin | 26 | 18 |
| Propranolol Hcl Er | Propranolol Hcl | 26 | suppressed |
| Ramipril | Ramipril | 26 | suppressed |
| Sucralfate | Sucralfate | 26 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 25 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 25 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 25 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 24 | suppressed |
| Nystatin | Nystatin | 24 | 15 |
| Sumatriptan Succinate | Sumatriptan Succinate | 24 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 23 | 18 |
| Dicyclomine Hcl | Dicyclomine Hcl | 23 | 11 |
| Farxiga | Dapagliflozin Propanediol | 23 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 23 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 23 | suppressed |
| Verapamil Er | Verapamil Hcl | 23 | suppressed |
| Bumetanide | Bumetanide | 22 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 22 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 22 | 15 |
| Lamotrigine | Lamotrigine | 22 | suppressed |
| Memantine Hcl | Memantine Hcl | 22 | suppressed |
| Nifedipine Er | Nifedipine | 22 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 22 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 22 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 21 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 21 | suppressed |
| Alprazolam | Alprazolam | 20 | suppressed |
| Celecoxib | Celecoxib | 20 | suppressed |
| Nyamyc | Nystatin | 20 | 11 |
| Olanzapine | Olanzapine | 20 | suppressed |
| Synthroid | Levothyroxine Sodium | 20 | suppressed |
| Mirtazapine | Mirtazapine | 19 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 19 | suppressed |
| Torsemide | Torsemide | 19 | suppressed |
| Xarelto | Rivaroxaban | 19 | suppressed |
| Glyburide-Metformin Hcl | Glyburide/Metformin Hcl | 18 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 18 | suppressed |
| Prasugrel Hcl | Prasugrel Hcl | 18 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 17 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 17 | suppressed |
| Chlorthalidone | Chlorthalidone | 17 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 17 | suppressed |
| Jantoven | Warfarin Sodium | 17 | suppressed |
| Linzess | Linaclotide | 17 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 17 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 16 | 12 |
| Repatha Sureclick | Evolocumab | 16 | suppressed |
| Topiramate | Topiramate | 16 | suppressed |
| Colchicine | Colchicine | 15 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Levofloxacin | Levofloxacin | 15 | 14 |
| Lorazepam | Lorazepam | 15 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 15 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Felodipine Er | Felodipine | 14 | suppressed |
| Gemfibrozil | Gemfibrozil | 14 | suppressed |
| Lovastatin | Lovastatin | 14 | suppressed |
| Carbamazepine | Carbamazepine | 13 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 13 | suppressed |
| Dulera | Mometasone/Formoterol | 13 | suppressed |
| Gentamicin Sulfate | Gentamicin Sulfate | 13 | 12 |
| Irbesartan | Irbesartan | 13 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 13 | suppressed |
| Rivastigmine | Rivastigmine | 13 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 13 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Trimethoprim | Trimethoprim | 13 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 12 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 12 | suppressed |
| Desmopressin Acetate | Desmopressin Acetate | 12 | suppressed |
| Enulose | Lactulose | 12 | suppressed |
| Fosinopril-Hydrochlorothiazide | Fosinopril/Hydrochlorothiazide | 12 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 12 | suppressed |
| Invokana | Canagliflozin | 12 | suppressed |
| Phenobarbital | Phenobarbital | 12 | suppressed |
| Premarin | Estrogens, Conjugated | 12 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 11 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 11 | suppressed |
| Lansoprazole | Lansoprazole | 11 | suppressed |
| Niacin Er | Niacin | 11 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 11 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $234.02 · 12 records | Novo Nordisk Inc | ABRYSVO, COMIRNATY, FARXIGA, Kerendia, MOUNJARO, NEXLETOL, NEXPLANON, NUVARING, Ozempic, PREVNAR 20, REXULTI, SPRAVATO, The Cologuard Plus Collection Kit, VALTOCO, Wegovy, ZEPBOUND | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error